CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 28, 2006--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that investigators from leading academic cancer-research centers and ARIAD will present data from six collaborative studies focused on compounds from ARIAD's oncogenic kinase inhibitor and bone-targeted mTOR inhibitor programs at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C., April 1 to April 5, 2006.
